Publication:
The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey

Simple item page
dc.contributor.authorsKilickap, S.; Olmez, O. F.; Cicin, I.; Demirci, U.; Alan, O.; Cabuk, D.; Sakalar, T.; Tatli, A. M.; Bugdayci, F. Basol; Eralp, Y.; Uysal, M.; Demirkazik, A.; Bilgin, B.; Yildiz, B.; Karaagac, M.; Okutur, K.; Sakin, A.
dc.date.accessioned2022-03-12T16:24:02Z
dc.date.accessioned2026-01-11T07:01:22Z
dc.date.available2022-03-12T16:24:02Z
dc.date.issued2018
dc.identifier.doidoiWOS:000459277303171
dc.identifier.eissn1569-8041
dc.identifier.issn0923-7534
dc.identifier.urihttps://hdl.handle.net/11424/226182
dc.identifier.wosWOS:000459277303171
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.relation.ispartofANNALS OF ONCOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleThe efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey
dc.typeconferenceObject
dspace.entity.typePublication
oaire.citation.endPage505
oaire.citation.startPage505
oaire.citation.titleANNALS OF ONCOLOGY
oaire.citation.volume29

Files

Collections

Araştırma Çıktıları